Targeting the Peptide Deformylase of Mycobacterium tuberculosis Leads to Drug Discovery

被引:4
|
作者
Singh, Vijai [1 ]
Somvanshi, Pallavi [1 ]
机构
[1] Bioinformat Ctr, Lucknow, Uttar Pradesh, India
关键词
Mycobacterium tuberculosis; Peptide deformylase; Docking; Phylogeny; Drugs;
D O I
10.2174/157018009789108286
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Peptide deformylase (PDF) is a ubiquitous bacterial metalloenzyme responsible to cleave the formyl group from nascent polypeptides, supporting in the maturation. It plays a vital role in the survival of bacterial cells which is conserved in the eubacteria and is considered to be an attractive target for developing new antibacterial agents. Homology modeling was employed for generation of 3-D structure of PDF of M. tuberculosis H37Rv and showed 92.5% amino acid in the allowed region of Ramachandran plot. PDF was used as target for a set of inhibitors with substantial structural differences. Docking results show that the BB-3497, BBS-54, Actinonin and BBS-02 bind with high affinity to enzyme active site. Phylogeny of PDF in M. tuberculosis H37Rv shows homology with other strains of pathogenic bacteria. These data validate PDF as a novel target for the design of a new generation of antimycobacterial agents.
引用
收藏
页码:487 / 493
页数:7
相关论文
共 50 条
  • [21] New drug targets for Mycobacterium tuberculosis
    Chopra, P
    Meena, LS
    Singh, Y
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2003, 117 : 1 - 9
  • [22] Discovery of new leads against Mycobacterium tuberculosis using scaffold hopping and shape based similarity
    Wavhale, Ravindra D.
    Martis, Elvis A. F.
    Ambre, Premlata K.
    Wan, Baojie
    Franzblau, Scott G.
    Iyer, Krishna R.
    Raikuvar, Kavita
    Macegoniuk, Katarzyna
    Berlicki, Lukasz
    Nandan, Santosh R.
    Coutinho, Evans C.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (17) : 4835 - 4844
  • [23] How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery
    Bhagwat, Amala
    Deshpande, Aditi
    Parish, Tanya
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [24] Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery
    Ekins, Sean
    Freundlich, Joel S.
    Hobrath, Judith V.
    White, E. Lucile
    Reynolds, Robert C.
    PHARMACEUTICAL RESEARCH, 2014, 31 (02) : 414 - 435
  • [25] Noise in a Metabolic Pathway Leads to Persister Formation in Mycobacterium tuberculosis
    Quigley, Jeffrey
    Lewis, Kim
    MICROBIOLOGY SPECTRUM, 2022, 10 (05):
  • [26] In Silico Strategies in Tuberculosis Drug Discovery
    Macalino, Stephani Joy Y.
    Billones, Junie B.
    Organo, Voltaire G.
    Carrillo, Maria Constancia O.
    MOLECULES, 2020, 25 (03):
  • [27] Drug resistance in Mycobacterium tuberculosis and targeting the l,d-transpeptidase enzyme
    Gokulan, Kuppan
    Varughese, Kottayil I.
    DRUG DEVELOPMENT RESEARCH, 2019, 80 (01) : 11 - 18
  • [28] Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
    Iqbal, Iram Khan
    Bajeli, Sapna
    Akela, Ajit Kumar
    Kumar, Ashwani
    PATHOGENS, 2018, 7 (01):
  • [29] Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors Targeting Mycobacterium tuberculosis Transcription
    Stephanie, Filia
    Saragih, Mutiara
    Tambunan, Usman Sumo Friend
    Siahaan, Teruna J.
    LIFE-BASEL, 2022, 12 (09):
  • [30] New active leads for tuberculosis booster drugs by structure-based drug discovery
    Tatum, Natalie J.
    Liebeschuetz, John W.
    Cole, Jason C.
    Frita, Rosangela
    Herledan, Adrien
    Baulard, Alain R.
    Willand, Nicolas
    Pohl, Ehmke
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2017, 15 (48) : 10245 - 10255